| TGF-beta3: A promising growth factor in engineered organogenesis. | |
| | |
MedLine Citation:
|
PMID: 18774917 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Engineered organogenesis is one of the most challenging areas on the cutting edge of regenerative medicine. Growth factors can affect cell proliferation, migration and differentiation profoundly, and thus play a critical role in tissue regeneration. TGF-betas produce a wide range of effects in different cells and tissues. TGF-beta3 is relatively recently discovered and studied. OBJECTIVE: To provide a broader understanding of the current state of TGF-beta3 in engineered osteogenesis, chondrogenesis, palate development, scar-free wound healing, odontogenesis and neurogenesis. METHODS: This review summarizes studies that explore or apply TGF-beta3 for organogenesis with engineering methodology and a regenerative medical perspective. RESULTS/CONCLUSION: TGF-beta3 has proven to be a competent growth factor in engineered organogenesis in vitro. In recent years, using TGF-beta3, more and more in vivo studies have yielded significant therapeutic achievements in animal models, which bear much promise for future medical application. |
| | |
Authors:
|
Jinghua Hao; Rohan R Varshney; Dong-An Wang |
Related Documents
:
|
4599597 - The present status of hypnosis. 12743647 - Establishing an agenda for biomedical informatics. 2782297 - Multiple homicides. 10256737 - Healthcare delivery in the federal republic of germany. 19469797 - Infraorbital dark circles: definition, causes, and treatment options. 1286557 - Donor screening. |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't; Review |
Journal Detail:
|
Title: Expert opinion on biological therapy Volume: 8 ISSN: 1744-7682 ISO Abbreviation: Expert Opin Biol Ther Publication Date: 2008 Oct |
Date Detail:
|
Created Date: 2008-09-08 Completed Date: 2008-12-29 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101125414 Medline TA: Expert Opin Biol Ther Country: England |
Other Details:
|
Languages: eng Pagination: 1485-93 Citation Subset: IM |
Affiliation:
|
Nanyang Technological University, School of Chemical and Biomedical Engineering, Division of Bioengineering, 70 Nanyang Drive, N1.3-B2-13, Singapore 637457, Republic of Singapore. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Cell Differentiation
/
drug effects Cell Movement / drug effects Cell Proliferation / drug effects Humans Recombinant Proteins / pharmacology Tissue Engineering* Tooth / growth & development Transforming Growth Factor beta3 / pharmacology* Wound Healing / drug effects |
| Chemical | |
Reg. No./Substance:
|
0/Recombinant Proteins; 0/Transforming Growth Factor beta3 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Cardiomyocytes from embryonic stem cells: towards human therapy.
Next Document: Cytokine therapy in cancer.